Pharmaceutical companies are increasingly collaborating with medical institutes and research centers in order to ramp up R&D pipelines of peptide drugs. This is expected to influence the growth of the global peptide based gastrointestinal disorders therapeutics market over the next couple of years. Rising prevalence of metabolic diseases and gastrointestinal disorders pertaining to the digestive system is prompting medical practitioners to utilize new therapeutics including peptides. In the near future, application of peptides is also expected to increase in other therapeutic areas as well. Moreover, technological advancement in peptide synthesis which include hybrid combination of liquid and solid synthesis and high-throughput approaches is expected to play a crucial role in development of more effective peptide based therapeutic drugs for treating gastrointestinal disorders. Such developments in the peptide therapeutics is also giving new hope to patients seeking affordable and effect therapeutic treatments. In addition, manufacturers are actively focusing on improving peptide properties, such as half-life and stability to address the various unmet medical needs.
According to the latest report published by Fact.MR, the global Peptide Based Gastrointestinal Disorders Therapeutics Market is set to reflect a double-digit CAGR between 2017 and 2022, to surpass a valuation of US$ 600 Mn.
Peptide is a biologically, naturally or artificially constituted form of amino acid monomers. Peptides can be utilized for treating various gastrointestinal disorders that mostly effect parts of the digestive system such as the gastrointestinal tract, large intestine, small intestine, stomach, esophagus, and rectum. Peptides are considered as an effective therapeutic agent for treating gastrointestinal diseases. Owing to their impressive preclinical results, an array of new peptide based gastrointestinal disorder therapeutics are expected to enter the market soon.
North America to Lead the Global Peptide Based Gastrointestinal Disorders Therapeutics Market
In terms of revenue, North America is expected to hold the dominant share of the global peptide based gastrointestinal disorders therapeutics market in 2017 and beyond. Factors such growing patient awareness and rapid adoption of peptide based therapeutics for treating various diseases are expected to support the growth of the market in the region. During the forecast period, the market in the region is projected to surge at a robust CAGR of 13.9%.
On the basis of drugs, the linaclotide segment is expected to retain its dominant position over 2022. Currently, the segment accounts for more than two-third share of the market in terms of revenue. Towards the end of the forecast period, the linaclotide segment is estimated to reach a market valuation in excess of US$ 466 Mn.
Shire plc, Ironwood Pharmaceuticals, Inc., Astellas Pharma Inc., Allergan plc, Accredo Health Group, Inc., are the key market players profiled in the Fact.MR’s report. A majority of these companies are channelizing investment in further expansion of their product portfolio. This, in turn, is anticipated to result in introduction of more efficacious peptide based therapeutic drugs for curing gastrointestinal ailments.